Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System

Condition(s) studied

Investigational drug(s) / intervention(s)

Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.: Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.

Study summary

This study is an exploratory cohort study conducted under real-world conditions, aiming to evaluate the feasibility of an artificial intelligence (AI)-guided standard treatment selection model for advanced solid tumors, as well as its superiority compared to clinician-selected treatment plans. A multi-agent system based on multimodal AI models will rank the priority of standard treatment options based on the personalized information of the patients, including including demographics, clinical information, and multi-omics data. The final treatment plan will be jointly selected by the patient and the clinician from the AI-recommended options, thereby delivering a personalized treatment.

Eligibility

Primary outcome measure(s)

• Progression-free survival (PFS) — Every 6 weeks, up to 2 years since enrollment
  Defined as the time from enrollment to documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first.

Trial sites (1)

More NING LI trials in China

Other trials for the same condition